Treating Alopecia Areata: Current Practices Versus New Directions

Am J Clin Dermatol. 2017 Feb;18(1):67-75. doi: 10.1007/s40257-016-0230-4.

Abstract

Alopecia areata (AA) is non-scarring hair loss resulting from an autoimmune disorder. Severity varies from patchy hair loss that often spontaneously resolves to severe and chronic cases that can progress to total loss of scalp and body hair. Many treatments are available; however, the efficacy of these treatments has not been confirmed, especially in severe cases, and relapse rates are high. First-line treatment often includes corticosteroids such as intralesional or topical steroids for mild cases and systemic steroids or topical immunotherapy with diphenylcyclopropenone or squaric acid dibutylester in severe cases. Minoxidil and bimatoprost may also be recommended, usually in combination with another treatment. Ongoing research and new insights into mechanisms have led to proposals of innovative therapies. New directions include biologics targeting immune response as well as lasers and autologous platelet-rich plasma therapy. Preliminary data are encouraging, and it is hoped this research will translate into new options for the treatment of AA in the near future.

Publication types

  • Review

MeSH terms

  • Alopecia Areata / pathology
  • Alopecia Areata / therapy*
  • Animals
  • Biological Products / therapeutic use
  • Dermatologic Agents / administration & dosage*
  • Dermatologic Agents / therapeutic use
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunotherapy / methods*
  • Laser Therapy / methods
  • Platelet-Rich Plasma
  • Recurrence

Substances

  • Biological Products
  • Dermatologic Agents
  • Glucocorticoids